Results of Switchback From Ranibizumab to Aflibercept in Patients With Exudative Age-Related Macular Degeneration

Clinical Ophthalmology - New Zealand
doi 10.2147/opth.s206910
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Informa UK Limited

Related search

Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration With Good Visual Acuity: 2-Year Results of a Prospective Study

Clinical Ophthalmology
Ophthalmology
2018English

Pharmacogenetics of Complement Factor H (Y402H) and Treatment of Exudative Age-Related Macular Degeneration With Ranibizumab

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2008English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Alternative Therapies in Exudative Age Related Macular Degeneration

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
1998English

Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)

BMC Geriatrics
GerontologyGeriatrics
2010English

Comparison of the Effect Between Pegaptanib and Ranibizumab on Exudative Age-Related Macular Degeneration With Small Lesion Size

Clinical Ophthalmology
Ophthalmology
2012English

Early Signs of Exudative Age-Related Macular Degeneration in Asians

Optometry and Vision Science
OptometryOphthalmology
2014English

Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data From an Observational Study

Ophthalmology
Ophthalmology
2016English

Two-Year Outcome of Treat-And-Extend Aflibercept After Ranibizumab in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Patients

Clinical Ophthalmology
Ophthalmology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy